Spruce Biosciences (SPRB) News Today $0.49 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)November 13, 2024 | markets.businessinsider.comSpruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?November 13, 2024 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives $5.00 Average PT from AnalystsNovember 13, 2024 | americanbankingnews.comSpruce Biosciences Reports Q3 2024 Earnings and UpdatesNovember 11, 2024 | tipranks.comSpruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNovember 11, 2024 | finanznachrichten.deSpruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach OutNovember 1, 2024 | stockhouse.comSpruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation ConferenceOctober 28, 2024 | businesswire.comSpruce Biosciences (NASDAQ:SPRB) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAnalysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Spruce Biosciences (SPRB)September 12, 2024 | markets.businessinsider.comThe Schall Law Firm Is Looking Into Whether Spruce Biosciences, Inc. Committed Securities Fraud And The Firm Wants Affected Shareholders To Reach OutSeptember 10, 2024 | stockhouse.comSpruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comThe Schall Law Firm Is Investigating Spruce Biosciences Inc For Potential Securities Law Violations And Investors Are Urged To Reach OutAugust 25, 2024 | stockhouse.comAn Securities Fraud Inquiry Has Been Opened Into Spruce Biosciences Inc And The Schall Law Firm Seeks Shareholder ParticipationAugust 24, 2024 | stockhouse.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and scPharmaceuticals (SCPH)August 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Spruce Biosciences Amid Anticipated Positive Clinical Trial Outcomes and Strong Financial PositionAugust 14, 2024 | markets.businessinsider.comSpruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesAugust 13, 2024 | finance.yahoo.comSPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q2 2024August 13, 2024 | investorplace.comOptimistic Outlook for Spruce Biosciences: Tildacerfont’s Market Potential Amidst Upcoming Trial DataJuly 26, 2024 | markets.businessinsider.comSpruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)June 4, 2024 | businesswire.comSpruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024June 3, 2024 | businesswire.comSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | finance.yahoo.comSpruce Biosciences to Participate in the Jefferies Global Healthcare ConferenceMay 23, 2024 | businesswire.comHold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising CompetitionMay 16, 2024 | markets.businessinsider.comSpruce Biosciences, Inc. (SPRB)May 16, 2024 | finance.yahoo.comBuy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial PositionMay 15, 2024 | markets.businessinsider.comSPRB Stock Earnings: Spruce Biosciences Beats EPS, Beats Revenue for Q1 2024May 13, 2024 | msn.comSpruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesMay 13, 2024 | businesswire.comSpruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 30, 2024 | finance.yahoo.comSpruce Biosciences Inc (SPRB)April 26, 2024 | investing.comSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual MeetingApril 22, 2024 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBApril 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 27, 2024 | prnewswire.comRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)March 23, 2024 | finance.yahoo.comHoldings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) StockMarch 22, 2024 | insidertrades.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBMarch 19, 2024 | prnewswire.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Major Shareholder Holdings A/S Novo Sells 1,912,316 SharesMarch 19, 2024 | insidertrades.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target PriceMarch 16, 2024 | finance.yahoo.comSpruce Biosciences (NASDAQ:SPRB) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs lowered shares of Spruce Biosciences from an "outperform" rating to a "market perform" rating in a report on Thursday.March 15, 2024 | marketbeat.comSpruce Biosciences Shares Dive 74% After Terminating Genetic Disease Study, Cutting StaffMarch 14, 2024 | marketwatch.comSpruce Biosciences' Hormone Treatment Stumbles In Trials, Prompts Stock FreefallMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences, Inc. (SPRB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 14, 2024 | businesswire.comStocks to Watch: Spruce Biosciences, UiPathMarch 14, 2024 | marketwatch.comSpruce Biosciences FY23 Loss Widens, CAHmelia-203 Study Fails; Stock Down In Pre-marketMarch 14, 2024 | markets.businessinsider.comWhy Is Rare Endocrine Disorder-Focused Spruce Biosciences Stock Plummeting On Thursday?March 14, 2024 | msn.comSpruce Biosciences (NASDAQ:SPRB) Downgraded by GuggenheimGuggenheim cut Spruce Biosciences from a "buy" rating to a "neutral" rating in a research report on Thursday.March 14, 2024 | marketbeat.comWhy Is Spruce Biosciences (SPRB) Stock Down 78% Today?March 14, 2024 | investorplace.comBuy Rating Affirmed for Spruce Biosciences Amid Clinical Trial Optimism and Advancing Dose CohortsMarch 14, 2024 | markets.businessinsider.comSpruce Biosciences stock craters 75% on failed Phase 2 studyMarch 13, 2024 | msn.comSpruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial SetbacksMarch 13, 2024 | finance.yahoo.comTrading was temporarily halted for "SPRB" at 04:03 PM with a stated reason of "News pending."March 13, 2024 | marketbeat.com Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss. Click here to get the details. SPRB Media Mentions By Week SPRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRB News Sentiment▼-0.070.45▲Average Medical News Sentiment SPRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRB Articles This Week▼01▲SPRB Articles Average Week Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Clearside Biomedical News Today Chimerix News Today PDS Biotechnology News Today I-Mab News Today ESSA Pharma News Today Aerovate Therapeutics News Today Werewolf Therapeutics News Today Vistagen Therapeutics News Today Ovid Therapeutics News Today BioAtla News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts